hyperuricemia Diabetes
Conditions
Interventions
Patients with hyperuricemia (serum uric acid level &
8 mg/dL) complicating diabetic nephropathy [stage 3A (GFR <
60 mL/minute/1.73 m2, proteinuria <
1 g/day) or stage 3B (GFR <
60 mL/minute/1.73 m2, proteinuria &
1 g/day)], who have failed to control the serum uric acid level at 6.0 mg/dL or lower even with 20 mg/day of febuxostat administered orally for at least 4 weeks and who have provided consent to partic
8 mg/dL) complicating diabetic nephropathy who have failed to control serum uric acid level at 6.0 mg/dL or lower even after taking febuxostat at 20 mg/day for at least 4 weeks.
Sponsors
Gifu University hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with hyperuricemia (serum uric acid level &#8805; 8 mg/dL) complicating diabetic nephropathy who have failed to control serum uric acid level at 6.0 mg/dL or lower even after taking febuxostat at 20 mg/day for at least 4 weeks.
Exclusion criteria
Exclusion criteria: (1) Patients contraindicated for benzbromarone, including 1) patients with hepatic disorders [ALT (GPT) &#8805; 100 IU/L], 2) patients with renal calculus and/or with severe renal function impairment (diabetic nephropathy stage 4 or more severe), 3) pregnant or possibly pregnant women, and 4) patients with a history of hypersensitivity to any ingredient of the product; (2) Patients contraindicated for febuxostat, including 1) patients with a history of hypersensitivity to any ingredient of the product and 2) patients on treatment with mercaptopurine hydrate or azathioprine; and (3) Other patients judged inappropriate by the physician in charge.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| improvement of hyperuricemia | — |
Countries
Japan
Contacts
Public ContactKatsumi Iizuka
Gifu university hospital Department of diabetes and meatbolism
Outcome results
None listed